ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

R-Pharm, Hoffmann-La Roche and Novartis side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

R-Pharm×Hoffmann-La Roche×Novartis×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

R-PharmHoffmann-La RocheNovartis
studies on the registry782,7443,902
open to participants now6114212
phase 3 studies under way69594
reach primary completion within a year176128
programswith a study of their own in two years780+25 named only77+7 named only

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseR-PharmHoffmann-La RocheNovartis
Phase 1

R-Pharm: 2 of its 7 programs at phase 1

  1. ocrelizumabphase 1
  2. Panitumumabphase 1
29%

Hoffmann-La Roche: 33 of its 80 programs at phase 1

  1. RAY121phase 1
  2. clesitamigphase 1
  3. P-CD19CD20-ALLO1 Cellsphase 1
  4. Anti-c-Met Antibody-drug Conjugate YL211phase 1
  5. AQUA07phase 1

and 28 more — sign in to see them all

41%

Novartis: 16 of its 77 programs at phase 1

  1. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1
  2. HJB647phase 1
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1
  5. Actinium Ac 225-ETN029phase 1

and 11 more — sign in to see them all

21%
Phase 2

R-Pharm: 1 of its 7 programs at phase 2

  1. RS-113phase 2
14%

Hoffmann-La Roche: 18 of its 80 programs at phase 2

  1. tifeglipronphase 2
  2. autogene cevumeranphase 2
  3. hyaluronidase (human recombinant)phase 2
  4. RO7568282phase 2
  5. tambotatug pelitecanphase 2

and 13 more — sign in to see them all

23%

Novartis: 35 of its 77 programs at phase 2

  1. Lutetium-177phase 2
  2. rapcabtagene autoleucelphase 2
  3. DDY391phase 2
  4. arumakimigphase 2
  5. QCZ484phase 2

and 30 more — sign in to see them all

45%
Phase 3

R-Pharm: 4 of its 7 programs at phase 3

  1. goflikiceptphase 3
  2. olokizumabphase 3
  3. RPH-051phase 3
  4. Cetuximabphase 3
57%

Hoffmann-La Roche: 22 of its 80 programs at phase 3

  1. inavolisibphase 3
  2. afimkibartphase 3
  3. giredestrantphase 3
  4. divarasibphase 3
  5. glofitamabphase 3

and 17 more — sign in to see them all

28%

Novartis: 18 of its 77 programs at phase 3

  1. remibrutinibphase 3
  2. ianalumabphase 3
  3. iptacopanphase 3
  4. pelabresibphase 3
  5. pelacarsenphase 3

and 13 more — sign in to see them all

23%
Approved, new studies00%

Hoffmann-La Roche: 7 of its 80 programs at approved, new studies

  1. ocrelizumabapproved, new study
  2. Ranibizumabapproved, new study
  3. emicizumabapproved, new study
  4. faricimabapproved, new study
  5. Trastuzumabapproved, new study

and 2 more — sign in to see them all

9%

Novartis: 8 of its 77 programs at approved, new studies

  1. inclisiranapproved, new study
  2. Alpelisibapproved, new study
  3. asciminibapproved, new study
  4. secukinumabapproved, new study
  5. ruxolitinibapproved, new study

and 3 more — sign in to see them all

10%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
R-Pharm1 readouts · 1 phase 3·····

R-Pharm, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. olokizumabphase 3 · Apr 9 · NCT06440746
······
Hoffmann-La Roche27 readouts · 7 phase 3

Hoffmann-La Roche, Nov ’26: 1 program whose next study reaches primary completion

  1. divarasibphase 3 · Nov 30 · NCT04302025

Hoffmann-La Roche, Dec ’26: 4 programs whose next study reaches primary completion

  1. RG6496phase 1 · Dec 1 · NCT07246941
  2. tifeglipronphase 2 · Dec 7 · NCT06982131
  3. afimkibartphase 3 · Dec 31 · NCT05910528
  4. inavolisibphase 3 · Dec 31 · NCT03006172

Hoffmann-La Roche, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. faricimabapproved, new study · Jan 26 · NCT05224102

Hoffmann-La Roche, Feb ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. Ranibizumabapproved, new study · Feb 4 · NCT04657289
  2. cevostamabphase 3 · Feb 26 · NCT05535244

Hoffmann-La Roche, Mar ’27: 4 programs whose next study reaches primary completion

  1. pegozaferminphase 3 · Mar 2 · NCT07835243
  2. glofitamabphase 3 · Mar 22 · NCT06624085
  3. RAY121phase 1 · Mar 31 · NCT06371417
  4. RO7812653phase 1 · Mar 31 · NCT07234942

Hoffmann-La Roche, Apr ’27: 3 programs whose next study reaches primary completion, 2 in phase 3

  1. enicepatidephase 3 · Apr 8 · NCT07626515
  2. Crovalimabphase 3 · Apr 18 · NCT04432584
  3. baloxavirphase 3 · Apr 30 · NCT07827599

Hoffmann-La Roche, May ’27: 1 program whose next study reaches primary completion

  1. RO7806881phase 1 · May 11 · NCT07271693

Hoffmann-La Roche, Jun ’27: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. fenebrutinibphase 3 · Jun 8 · NCT07161258
  2. DONQ52phase 2 · Jun 15 · NCT07239336
  3. RO7890597phase 1 · Jun 15 · NCT07797478
  4. astegolimabphase 3 · Jun 30 · NCT05878769

Hoffmann-La Roche, Jul ’27: 2 programs whose next study reaches primary completion

  1. giredestrantphase 3 · Jul 31 · NCT03332797
  2. trontinemabphase 3 · Jul 31 · NCT04639050

Hoffmann-La Roche, Aug ’27: 2 programs whose next study reaches primary completion

  1. RO7837195phase 2 · Aug 25 · NCT06979336
  2. bizrolertinibphase 3 · Aug 31 · NCT05593094

Hoffmann-La Roche, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zemocimigphase 3 · Sep 23 · NCT07416526

Hoffmann-La Roche, Oct ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. mosunetuzumabphase 3 · Oct 1 · NCT05207670
  2. emicizumabapproved, new study · Oct 6 · NCT06998524
Novartis27 readouts · 5 phase 3

Novartis, Nov ’26: 1 program whose next study reaches primary completion, 1 in phase 3

  1. inclisiranapproved, new study · Nov 27 · NCT06501443

Novartis, Dec ’26: 5 programs whose next study reaches primary completion

  1. luxdegalutamidephase 2 · Dec 3 · NCT06991556
  2. HJB647phase 1 · Dec 8 · NCT07465653
  3. gallium 68 PSMA-11phase 2 · Dec 23 · NCT05849298
  4. iptacopanphase 3 · Dec 30 · NCT06388941
  5. Lutetium-177phase 2 · Dec 30 · NCT05870579

Novartis, Jan ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. opnurasibphase 3 · Jan 25 · NCT04699188
  2. Alpelisibapproved, new study · Jan 28 · NCT05038735

Novartis, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. cipargaminphase 2 · Feb 4 · NCT07811908
  2. ganaplacidephase 3 · Feb 4 · NCT07811908
  3. remibrutinibphase 3 · Feb 22 · NCT06868212

Novartis, Mar ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. PKN605phase 2 · Mar 1 · NCT07797322
  2. EDI-048phase 2 · Mar 23 · NCT07249463
  3. ianalumabphase 3 · Mar 26 · NCT05639114

Novartis, Apr ’27: 4 programs whose next study reaches primary completion

  1. arumakimigphase 2 · Apr 22 · NCT07203001
  2. DII235phase 2 · Apr 26 · NCT07235046
  3. QCZ484phase 2 · Apr 28 · NCT07610278
  4. delpacibart zotadirsenphase 3 · Apr 30 · NCT06244082

Novartis, May ’27: 3 programs whose next study reaches primary completion

  1. GIA632phase 2 · May 17 · NCT07220577
  2. luxdegalutamidephase 2 · May 25 · NCT05067140
  3. Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565phase 1 · May 31 · NCT05397496
·

Novartis, Jul ’27: 3 programs whose next study reaches primary completion

  1. EYU688phase 2 · Jul 22 · NCT06006559
  2. LXE408phase 2 · Jul 22 · NCT06632600
  3. GXV-813phase 2 · Jul 29 · NCT07467993

Novartis, Aug ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zigakibartphase 3 · Aug 10 · NCT05852938
  2. YMI024phase 2 · Aug 15 · NCT07830719

Novartis, Sep ’27: 1 program whose next study reaches primary completion

  1. asciminibapproved, new study · Sep 3 · NCT04925479
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

R-Pharm

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Hoffmann-La Roche

New programs 4

  • RO7836748phase 1 · first study · Oct 23
  • RO7821657phase 1 · first study · Oct 14
  • RO7965032phase 2 · first study · Sep 25 · Geographic Atrophy
  • RO7830698phase 2 · first study · Sep 11 · Pulmonary Disease, Chronic Obstructive

Reached a new phase 1

Study stopped 1

  • RO7763505phase 1 · terminated Nov 17 · none of its studies left running“The development of RO7763505 for coronary artery disease has been discontinued.” · NCT07495813

Primary completion later 11

Novartis

New programs 5

  • pacibekitugphase 3 · first study · Nov 9 · Myocardial Infarction
  • DKB903phase 1 · first study · Nov 2 · Arthritis, Rheumatoid
  • TRB191phase 1 · first study · Oct 26 · Small Cell Lung Carcinoma
  • XEP527phase 1 · first study · Oct 26 · Schizophrenia
  • YMI024phase 2 · first study · Sep 15 · Coronary Artery Disease

Reached a new phase 1

Study stopped 6

  • remibrutinibphase 3 · terminated Nov 20“Sponsor decision based on pre-specified futility efficacy criteria being met.” · NCT06744920
  • Lutetium-177phase 1 · terminated Nov 17“Sponsor decision and not a consequence of any safety concerns.” · NCT06379217
  • pelacarsenphase 3 · terminated Nov 10“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT05900141
  • opnurasibphase 3 · terminated Nov 6“Business reasons and not based on any safety concerns.” · NCT05132075
  • ianalumabphase 2 · withdrawn Oct 15“The study was discontinued due to evolving scientific \& feasibility considerations that could adversely af…” · NCT07039422
  • pelacarsenphase 3 · withdrawn Oct 14“Study terminated by sponsor following the outcome of the Lp(a)HORIZON study (NCT04023552), which did not me…” · NCT07625306

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 41 in all. A program counts in each condition its studies name most.

ConditionR-PharmHoffmann-La RocheNovartis
Prostatic Neoplasmsall three · compare here

R-Pharm in Prostatic Neoplasms: 1 program

  1. RS-113phase 2

Their studies: R-Pharm’s studies of Prostatic Neoplasms in search

Hoffmann-La Roche in Prostatic Neoplasms: 3 programs

  1. inavolisibphase 3
  2. GDC-1261phase 2
  3. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Prostatic Neoplasms in search

Novartis in Prostatic Neoplasms: 13 programs

  1. Atrasentanphase 3
  2. actinium AC-225 vipivotide tetraxetanphase 3
  3. Gallium-68phase 3
  4. ARPIphase 3
  5. Lutetium-177phase 2

and 8 more — sign in to see them all

Their studies: Novartis’s studies of Prostatic Neoplasms in search

Breast Neoplasmsall three · compare here

R-Pharm in Breast Neoplasms: 1 program

  1. RPH-051phase 3

Their studies: R-Pharm’s studies of Breast Neoplasms in search

Hoffmann-La Roche in Breast Neoplasms: 6 programs

  1. inavolisibphase 3
  2. giredestrantphase 3
  3. bizrolertinibphase 3
  4. vustanaciclibphase 2
  5. GDC-0587phase 1

and 1 more — sign in to see them all

Their studies: Hoffmann-La Roche’s studies of Breast Neoplasms in search

Novartis in Breast Neoplasms: 6 programs

  1. Gallium-68phase 3
  2. Lutetium-177phase 2
  3. GVV858phase 2
  4. ERW316phase 2
  5. IEV407phase 1

and 1 more — sign in to see them all

Their studies: Novartis’s studies of Breast Neoplasms in search

Arthritis, Rheumatoidall three · compare here

R-Pharm in Arthritis, Rheumatoid: 2 programs

  1. olokizumabphase 3
  2. ocrelizumabphase 1

Their studies: R-Pharm’s studies of Arthritis, Rheumatoid in search

Hoffmann-La Roche in Arthritis, Rheumatoid: 3 programs

  1. afimkibartphase 3
  2. fenebrutinibphase 3
  3. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Arthritis, Rheumatoid in search

Carcinoma, Non-Small-Cell Lungall three · compare here

R-Pharm in Carcinoma, Non-Small-Cell Lung: 2 programs

  1. Cetuximabphase 3
  2. Panitumumabphase 1

Their studies: R-Pharm’s studies of Carcinoma, Non-Small-Cell Lung in search

Hoffmann-La Roche in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. divarasibphase 3
  2. tambotatug pelitecanphase 2
  3. AQUA07phase 1
  4. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Carcinoma, Non-Small-Cell Lung in search

Novartis in Carcinoma, Non-Small-Cell Lung: 4 programs

  1. opnurasibphase 3
  2. Lutetium-177phase 2
  3. Gallium Ga 68 NNS309phase 1
  4. 177Lu-DFC413phase 1

Their studies: Novartis’s studies of Carcinoma, Non-Small-Cell Lung in search

Colorectal Neoplasmsall three · compare here

R-Pharm in Colorectal Neoplasms: 2 programs

  1. Cetuximabphase 3
  2. Panitumumabphase 1

Their studies: R-Pharm’s studies of Colorectal Neoplasms in search

Hoffmann-La Roche in Colorectal Neoplasms: 5 programs

  1. inavolisibphase 3
  2. divarasibphase 3
  3. autogene cevumeranphase 2
  4. Lead Pb 203-DOTAMphase 1
  5. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Colorectal Neoplasms in search

Novartis in Colorectal Neoplasms: 1 program

  1. Gallium-68phase 3

Their studies: Novartis’s studies of Colorectal Neoplasms in search

Neoplasmsall three · compare here

R-Pharm in Neoplasms: 2 programs

  1. Cetuximabphase 3
  2. Panitumumabphase 1

Their studies: R-Pharm’s studies of Neoplasms in search

Hoffmann-La Roche in Neoplasms: 4 programs

  1. inavolisibphase 3
  2. lorlatinibphase 1
  3. Pan-RAS Inhibitor RG6505phase 1
  4. Trastuzumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Neoplasms in search

Novartis in Neoplasms: 2 programs

  1. tulmimetostatphase 2
  2. Alpelisibapproved, new study

Their studies: Novartis’s studies of Neoplasms in search

Lupus Nephritisall three · compare here

R-Pharm in Lupus Nephritis: 1 program

  1. ocrelizumabphase 1

Their studies: R-Pharm’s studies of Lupus Nephritis in search

Hoffmann-La Roche in Lupus Nephritis: 2 programs

  1. mosunetuzumabphase 3
  2. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Lupus Nephritis in search

Novartis in Lupus Nephritis: 2 programs

  1. ianalumabphase 3
  2. rapcabtagene autoleucelphase 2

Their studies: Novartis’s studies of Lupus Nephritis in search

Multiple Sclerosis, Chronic Progressiveall three · compare here

R-Pharm in Multiple Sclerosis, Chronic Progressive: 1 program

  1. ocrelizumabphase 1

Their studies: R-Pharm’s studies of Multiple Sclerosis, Chronic Progressive in search

Hoffmann-La Roche in Multiple Sclerosis, Chronic Progressive: 3 programs

  1. fenebrutinibphase 3
  2. RO7268489phase 2
  3. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Multiple Sclerosis, Chronic Progressive in search

Novartis in Multiple Sclerosis, Chronic Progressive: 1 program

  1. rapcabtagene autoleucelphase 2

Their studies: Novartis’s studies of Multiple Sclerosis, Chronic Progressive in search

Small Cell Lung Carcinoma2 of 3 · compare here–
Alzheimer Disease2 of 3 · compare here–

Hoffmann-La Roche in Alzheimer Disease: 5 programs

  1. trontinemabphase 3
  2. RO7568282phase 2
  3. nivegacetorphase 2
  4. RO7812653phase 1
  5. Immunoglobulin Gphase 1

Their studies: Hoffmann-La Roche’s studies of Alzheimer Disease in search

Novartis in Alzheimer Disease: 2 programs

  1. Oligonucleotides, Antisensephase 2
  2. VHB937phase 2

Their studies: Novartis’s studies of Alzheimer Disease in search

Dermatitis, Atopic2 of 3 · compare here–

Hoffmann-La Roche in Dermatitis, Atopic: 3 programs

  1. afimkibartphase 3
  2. astegolimabphase 3
  3. Cyclosporineapproved, new study

Their studies: Hoffmann-La Roche’s studies of Dermatitis, Atopic in search

Novartis in Dermatitis, Atopic: 4 programs

  1. GIA632phase 2
  2. GHZ339phase 2
  3. DCY636phase 1
  4. ruxolitinibapproved, new study

Their studies: Novartis’s studies of Dermatitis, Atopic in search

Multiple Myeloma2 of 3 · compare here–

Hoffmann-La Roche in Multiple Myeloma: 4 programs

  1. cevostamabphase 3
  2. hyaluronidase (human recombinant)phase 2
  3. RO7851624phase 1
  4. RO7875913phase 1

Their studies: Hoffmann-La Roche’s studies of Multiple Myeloma in search

Novartis in Multiple Myeloma: 2 programs

  1. pelabresibphase 3
  2. zigakibartphase 3

Their studies: Novartis’s studies of Multiple Myeloma in search

Geographic Atrophy2 of 3 · compare here–

Hoffmann-La Roche in Geographic Atrophy: 4 programs

  1. RO7965032phase 2
  2. avacincaptad pegolphase 1
  3. pegcetacoplanphase 1
  4. RO7669330phase 1

Their studies: Hoffmann-La Roche’s studies of Geographic Atrophy in search

Novartis in Geographic Atrophy: 1 program

  1. FWY003phase 2

Their studies: Novartis’s studies of Geographic Atrophy in search

Lupus Erythematosus, Systemic2 of 3 · compare here–

Hoffmann-La Roche in Lupus Erythematosus, Systemic: 3 programs

  1. cevostamabphase 3
  2. fenebrutinibphase 3
  3. P-CD19CD20-ALLO1 Cellsphase 1

Their studies: Hoffmann-La Roche’s studies of Lupus Erythematosus, Systemic in search

Lymphoma, B-Cell2 of 3 · compare here–

Hoffmann-La Roche in Lymphoma, B-Cell: 3 programs

  1. glofitamabphase 3
  2. mosunetuzumabphase 3
  3. bexobrutidegno phase

Their studies: Hoffmann-La Roche’s studies of Lymphoma, B-Cell in search

Macular Degeneration2 of 3 · compare here–

Hoffmann-La Roche in Macular Degeneration: 4 programs

  1. avacincaptad pegolphase 1
  2. pegcetacoplanphase 1
  3. Ranibizumabapproved, new study
  4. faricimabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Macular Degeneration in search

Novartis in Macular Degeneration: 1 program

  1. iptacopanphase 3

Their studies: Novartis’s studies of Macular Degeneration in search

Multiple Sclerosis2 of 3 · compare here

R-Pharm in Multiple Sclerosis: 1 program

  1. ocrelizumabphase 1

Their studies: R-Pharm’s studies of Multiple Sclerosis in search

Hoffmann-La Roche in Multiple Sclerosis: 4 programs

  1. fenebrutinibphase 3
  2. P-CD19CD20-ALLO1 Cellsphase 1
  3. RO7845860phase 1
  4. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Multiple Sclerosis in search

–
Renal Insufficiency2 of 3 · compare here–

Hoffmann-La Roche in Renal Insufficiency: 3 programs

  1. petrelintidephase 3
  2. tifeglipronphase 2
  3. lorlatinibphase 1

Their studies: Hoffmann-La Roche’s studies of Renal Insufficiency in search

Novartis in Renal Insufficiency: 2 programs

  1. PKN605phase 2
  2. asciminibapproved, new study

Their studies: Novartis’s studies of Renal Insufficiency in search

Glomerulonephritis, IGA2 of 3 · compare here–

Hoffmann-La Roche in Glomerulonephritis, IGA: 1 program

  1. sefaxersenphase 3

Their studies: Hoffmann-La Roche’s studies of Glomerulonephritis, IGA in search

Novartis in Glomerulonephritis, IGA: 3 programs

  1. iptacopanphase 3
  2. Atrasentanphase 3
  3. zigakibartphase 3

Their studies: Novartis’s studies of Glomerulonephritis, IGA in search

Arthritis, Juvenile2 of 3 · compare here

R-Pharm in Arthritis, Juvenile: 2 programs

  1. goflikiceptphase 3
  2. olokizumabphase 3

Their studies: R-Pharm’s studies of Arthritis, Juvenile in search

–

Novartis in Arthritis, Juvenile: 1 program

  1. arumakimigphase 2

Their studies: Novartis’s studies of Arthritis, Juvenile in search

Atherosclerosis2 of 3 · compare here–

Hoffmann-La Roche in Atherosclerosis: 1 program

  1. selnoflastphase 2

Their studies: Hoffmann-La Roche’s studies of Atherosclerosis in search

Novartis in Atherosclerosis: 2 programs

  1. pelacarsenphase 3
  2. inclisiranapproved, new study

Their studies: Novartis’s studies of Atherosclerosis in search

Hemoglobinuria, Paroxysmal2 of 3 · compare here–

Hoffmann-La Roche in Hemoglobinuria, Paroxysmal: 2 programs

  1. Crovalimabphase 3
  2. pegcetacoplanphase 1

Their studies: Hoffmann-La Roche’s studies of Hemoglobinuria, Paroxysmal in search

Novartis in Hemoglobinuria, Paroxysmal: 1 program

  1. iptacopanphase 3

Their studies: Novartis’s studies of Hemoglobinuria, Paroxysmal in search

Hypertension2 of 3 · compare here–

Hoffmann-La Roche in Hypertension: 1 program

  1. zilebesiranphase 3

Their studies: Hoffmann-La Roche’s studies of Hypertension in search

Novartis in Hypertension: 2 programs

  1. QCZ484phase 2
  2. HJB647phase 1

Their studies: Novartis’s studies of Hypertension in search

Lymphoma, Non-Hodgkin2 of 3 · compare here–

Hoffmann-La Roche in Lymphoma, Non-Hodgkin: 2 programs

  1. glofitamabphase 3
  2. mosunetuzumabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Non-Hodgkin in search

Novartis in Lymphoma, Non-Hodgkin: 1 program

  1. blinatumomabphase 2

Their studies: Novartis’s studies of Lymphoma, Non-Hodgkin in search

Schizophrenia2 of 3 · compare here–

Hoffmann-La Roche in Schizophrenia: 1 program

  1. ralmitarontphase 2

Their studies: Hoffmann-La Roche’s studies of Schizophrenia in search

Novartis in Schizophrenia: 2 programs

  1. GXV-813phase 2
  2. XEP527phase 1

Their studies: Novartis’s studies of Schizophrenia in search

Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here

R-Pharm in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. Cetuximabphase 3
  2. Panitumumabphase 1

Their studies: R-Pharm’s studies of Squamous Cell Carcinoma of Head and Neck in search

–

Novartis in Squamous Cell Carcinoma of Head and Neck: 1 program

  1. Alpelisibapproved, new study

Their studies: Novartis’s studies of Squamous Cell Carcinoma of Head and Neck in search

Anemia, Sickle Cell2 of 3 · compare here–

Hoffmann-La Roche in Anemia, Sickle Cell: 1 program

  1. Crovalimabphase 3

Their studies: Hoffmann-La Roche’s studies of Anemia, Sickle Cell in search

Novartis in Anemia, Sickle Cell: 1 program

  1. ITU512phase 2

Their studies: Novartis’s studies of Anemia, Sickle Cell in search

Atypical Hemolytic Uremic Syndrome2 of 3 · compare here–

Hoffmann-La Roche in Atypical Hemolytic Uremic Syndrome: 1 program

  1. Crovalimabphase 3

Their studies: Hoffmann-La Roche’s studies of Atypical Hemolytic Uremic Syndrome in search

Novartis in Atypical Hemolytic Uremic Syndrome: 1 program

  1. iptacopanphase 3

Their studies: Novartis’s studies of Atypical Hemolytic Uremic Syndrome in search

Bronchiolitis Obliterans Syndrome2 of 3 · compare here–

Hoffmann-La Roche in Bronchiolitis Obliterans Syndrome: 1 program

  1. Cyclosporineapproved, new study

Their studies: Hoffmann-La Roche’s studies of Bronchiolitis Obliterans Syndrome in search

Novartis in Bronchiolitis Obliterans Syndrome: 1 program

  1. asciminibapproved, new study

Their studies: Novartis’s studies of Bronchiolitis Obliterans Syndrome in search

Coronary Artery Disease2 of 3 · compare here–

Hoffmann-La Roche in Coronary Artery Disease: 1 program

  1. RO7763505phase 1

Their studies: Hoffmann-La Roche’s studies of Coronary Artery Disease in search

Novartis in Coronary Artery Disease: 1 program

  1. YMI024phase 2

Their studies: Novartis’s studies of Coronary Artery Disease in search

COVID-192 of 3 · compare here

R-Pharm in COVID-19: 1 program

  1. olokizumabphase 3

Their studies: R-Pharm’s studies of COVID-19 in search

Hoffmann-La Roche in COVID-19: 1 program

  1. astegolimabphase 3

Their studies: Hoffmann-La Roche’s studies of COVID-19 in search

–
Huntington Disease2 of 3 · compare here–

Hoffmann-La Roche in Huntington Disease: 1 program

  1. RG6496phase 1

Their studies: Hoffmann-La Roche’s studies of Huntington Disease in search

Novartis in Huntington Disease: 1 program

  1. votoplamphase 3

Their studies: Novartis’s studies of Huntington Disease in search

Lymphoma2 of 3 · compare here–

Hoffmann-La Roche in Lymphoma: 1 program

  1. glofitamabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma in search

Novartis in Lymphoma: 1 program

  1. pelabresibphase 3

Their studies: Novartis’s studies of Lymphoma in search

Lymphoma, Follicular2 of 3 · compare here–

Hoffmann-La Roche in Lymphoma, Follicular: 1 program

  1. mosunetuzumabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Follicular in search

Novartis in Lymphoma, Follicular: 1 program

  1. pelabresibphase 3

Their studies: Novartis’s studies of Lymphoma, Follicular in search

Lymphoma, Large B-Cell, Diffuse2 of 3 · compare here–

Hoffmann-La Roche in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. glofitamabphase 3

Their studies: Hoffmann-La Roche’s studies of Lymphoma, Large B-Cell, Diffuse in search

Novartis in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. blinatumomabphase 2

Their studies: Novartis’s studies of Lymphoma, Large B-Cell, Diffuse in search

Multiple Sclerosis, Relapsing-Remitting2 of 3 · compare here

R-Pharm in Multiple Sclerosis, Relapsing-Remitting: 1 program

  1. ocrelizumabphase 1

Their studies: R-Pharm’s studies of Multiple Sclerosis, Relapsing-Remitting in search

Hoffmann-La Roche in Multiple Sclerosis, Relapsing-Remitting: 1 program

  1. ocrelizumabapproved, new study

Their studies: Hoffmann-La Roche’s studies of Multiple Sclerosis, Relapsing-Remitting in search

–
Muscular Atrophy, Spinal2 of 3 · compare here–

Hoffmann-La Roche in Muscular Atrophy, Spinal: 1 program

  1. emugrobartphase 3

Their studies: Hoffmann-La Roche’s studies of Muscular Atrophy, Spinal in search

Novartis in Muscular Atrophy, Spinal: 1 program

  1. Onasemnogene Abeparvovec-brveapproved, new study

Their studies: Novartis’s studies of Muscular Atrophy, Spinal in search

Muscular Dystrophy, Facioscapulohumeral2 of 3 · compare here–

Hoffmann-La Roche in Muscular Dystrophy, Facioscapulohumeral: 1 program

  1. emugrobartphase 3

Their studies: Hoffmann-La Roche’s studies of Muscular Dystrophy, Facioscapulohumeral in search

Novartis in Muscular Dystrophy, Facioscapulohumeral: 1 program

  1. AOC 1020phase 3

Their studies: Novartis’s studies of Muscular Dystrophy, Facioscapulohumeral in search

Myasthenia Gravis2 of 3 · compare here–

Hoffmann-La Roche in Myasthenia Gravis: 1 program

  1. hyaluronidase (human recombinant)phase 2

Their studies: Hoffmann-La Roche’s studies of Myasthenia Gravis in search

Novartis in Myasthenia Gravis: 1 program

  1. remibrutinibphase 3

Their studies: Novartis’s studies of Myasthenia Gravis in search

Ovarian Neoplasms2 of 3 · compare here–

Hoffmann-La Roche in Ovarian Neoplasms: 1 program

  1. giredestrantphase 3

Their studies: Hoffmann-La Roche’s studies of Ovarian Neoplasms in search

Novartis in Ovarian Neoplasms: 1 program

  1. Alpelisibapproved, new study

Their studies: Novartis’s studies of Ovarian Neoplasms in search

Pancreatic Neoplasms2 of 3 · compare here–

Hoffmann-La Roche in Pancreatic Neoplasms: 1 program

  1. tambotatug pelitecanphase 2

Their studies: Hoffmann-La Roche’s studies of Pancreatic Neoplasms in search

Novartis in Pancreatic Neoplasms: 1 program

  1. ruxolitinibapproved, new study

Their studies: Novartis’s studies of Pancreatic Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: R-Pharm 4 of 7 · Hoffmann-La Roche 39 of 80 · Novartis 56 of 77 programs (39 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Hoffmann-La Roche: 25, Novartis: 7).